Monday, June 30, 2025 6/30/2025

Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness

Award Number: U01CA271400
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/17/2022
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness - PROJECT SUMMARY Prostate cancer risk assessment governs decisions across a spectrum of local-regional disease from whether to biopsy to whether to intensify treatment using multimodality therapy. RNA transcript-based signatures have rapidly been incorporated into such determinations, along with Gleason Score (now termed Grade Group or GG). The significance of the proposed work is that there is a pressing need for optimization and standardization of preanalytic conditions for determination of highest GG and expression of Prostate Transcripts of Aggressiveness (PTAs), especially when working with biopsy biospecimens. These preanalytic variables extend from tissue procurement to preservation of transcript marker integrity such that appropriate risk is assigned for each patient. Obtaining prostate biopsies with multiparametric (mp) MRI-guidance has rapidly gained acceptance but there is little information about how prostate mpMRI contributes to the preanalytic variables that must be recognized and managed in clinical trials and clinical practice. There are considerable variances in the location and number of prostate biopsies collected and in the handling of the tissue from fixation to embedding to processing for testing of PTAs. As transcriptomic tests become more incorporated into clinical trials and practice, the tolerance of an assay for routinely encountered preanalytic variables must be considered in the formalization of standard operating procedures (SOPs). We will evaluate mpMRI targeted prostate biopsy specimens obtained from patients enrolled in five existing clinical trials in which the MR images are interpreted using both the standard-of- care reporting system for prostate (PIRADSv2.1) and a more advanced, automated, and portable quantitative mpMRI pixel by pixel-based scoring system termed the “Habitat Risk Score” (HRS). While PIRADS provides a critically important framework for prostate mpMRI image acquisition and interpretation, it is limited by reader subjectivity and variability in defining biopsy regions. In this project the impact of refined prostate biopsy procurement is paired with delineation of tissue processing variables for the classification of the most aggressive prostate cancer attributes defined by GG and PTAs. The Decipher Genomic Classifier (GC) score is representative of PTAs incorporated into signatures and is routinely used in clinical practice, is included in current NCCN recommendations, and is part of a combined GG/GC risk model (Spratt model). Our proof-of-principal studies on the impact of preanalytic variables examine highest GG and GC score, as well as effects on >400 PTAs. We hypothesize that mpMRI HRS directed tissue procurement will result in tissue more representative of prostate cancer risk, as determined by combined GG/GC score, as compared to tissue procurement directed by mpMRI PIRADS suspicion scores (Aim 1), that GG/Decipher GC risk will be adequately defined by 2 cores, as compared to 4 (Aim 2) and that the definition of preanalytic processing variables and revised analytic methods will result in improved integrity of PTAs (Aim 3).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $351,131 )
2025	2025	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Treatment Research	000	4	5/30/2025	NON-COMPETING CONTINUATION	$351,131
														Subtotal = $351,131

Issue Date FY: 2024 ( Subtotal = $276,871 )
2024	2024	UNIVERSITY OF MIAMI	1320 S DIXIE HWY STE 1200	CORAL GABLES	FL	33146	MIAMI-DADE	USA	Cancer Treatment Research	000	3	7/10/2024	NON-COMPETING CONTINUATION	$276,871
														Subtotal = $276,871

Issue Date FY: 2023 ( Subtotal = $344,109 )
2023	2023	UNIVERSITY OF MIAMI	1400 NW 10TH AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Treatment Research	000	2	7/18/2023	NON-COMPETING CONTINUATION	$344,109
														Subtotal = $344,109

Issue Date FY: 2022 ( Subtotal = $351,131 )
2022	2022	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Treatment Research	000	1	6/17/2022	NEW	$351,131
														Subtotal = $351,131

Grand Total All Awards = $1,323,242

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness

Award Number: U01CA271400

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/17/2022

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer